

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Todd R. Henderson et al.

Application No.: Continuation of 10/192,318

Group Art Unit: N/A

Filed: April 15, 2004

Examiner: Not Yet Assigned

For: THE USE OF ANABOLIC AGENTS, ANTI-
CATABOLIC AGENTS, ANTIOXIDANT
AGENTS, AND ANALGESICS FOR
PROTECTION, TREATMENT AND REPAIR
OF CONNECTIVE TISSUES IN HUMANS
AND ANIMALS

INFORMATION DISCLOSURE STATEMENT

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08a/b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information

Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

- ☐ c. Attached is our Check No. _____ in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:


- ☒ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. 10/192,318, filed July 11, 2002, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☒ 8. Copies of the documents were cited by or submitted to the Office in Application Nos. 10/192,318, filed July 11, 2002 and 09/274,881, filed March 23, 1999 (now abandoned), which are relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08a/b, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740, referencing Docket No. 024047.370B-US02.

Dated: April 15, 2004

Respectfully submitted,

By 
Natalie M. Derzko
Registration No.: 48,102
COVINGTON & BURLING
1201 Pennsylvania Avenue, N.W.
Washington, DC 20004-2401
(202) 662-6000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	8	Attorney Docket Number	024047.370B-US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2,881,173-B1	04-07-1959	Wilhelm Wenner	
	AB	US-3,624,114-B1	11-30-1971	Jean V. Morelle	
	AC	US-3,882,228-B1	05-06-1975	Boncey et al.	
	AD	US-3,887,700-B1	06-03-1975	Boncey et al.	
	AE	US-3,993,775-B1	11-23-1976	Williams	
	AF	US-4,100,160-B1	07-11-1978	Walser	
	AG	US-4,296,127-B1	10-20-1981	Walser	
	AH	US-4,309,415-B1	01-05-1982	Horrobin	
	AI	US-4,314,989-B1	02-09-1982	Rosen	
	AJ	US-4,333,484-B1	06-08-1982	Keritsis	
	AK	US-4,386,072-B1	05-31-1983	Horrobin et al.	
	AL	US-4,624,919-B1	11-25-1986	Kokusho et al.	
	AM	US-4,683,298-B1	07-28-1987	Yalpani	
	AN	US-4,699,900-B1	10-13-1987	Bayol et al.	
	AO	US-4,713,373-B1	12-15-1987	Bayol et al.	
	AP	US-4,855,136-B1	08-08-1989	Horrobin et al.	
	AQ	US-4,900,724-B1	02-13-1990	Kato et al.	
	AR	US-4,925,833-B1	05-15-1990	McNamara et al.	
	AS	US-4,994,457-B1	02-19-1991	Crawford et al.	
	AT	US-5,084,482-B1	01-28-1992	Hirsch et al.	
	AU	US-5,137,712-B1	08-11-1992	Kask et al.	
	AV	US-5,145,841-B1	09-08-1992	Cullis-Hill et al.	
	AW	US-5,215,759-B1	06-01-1993	Mausner	
	AX	US-5,225,192-B1	07-06-1993	Lovrecich	
	AY	US-5,258,371-B1	11-02-1993	Golub et al.	
	AZ	US-5,262,163-B1	11-16-1993	Rancurel	
	AA1	US-5,288,503-B1	02-22-1994	Wood et al.	
	AB1	US-5,354,560-B1	10-11-1994	Lovrecich	
	AC1	US-5,364,845-B1	11-15-1994	Henderson	
	AD1	US-5,354,853-B1	10-11-1994	Staveski et al.	
	AE1	US-5,411,988-B1	05-02-1995	Bockow et al.	
	AF1	US-5,422,111-B1	06-06-1995	Huc et al.	
	AG1	US-5,449,521-B1	09-12-1995	Lovrecich	
	AH1	US-5,474,757-B1	12-12-1995	Yang	
	AI1	US-5,480,873-B1	01-02-1996	Brunavs et al.	
	AJ1	US-5,498,411-B1	03-12-1996	Rancurel	
	AK1	US-5,569,469-B1	10-29-1996	Lovrecich	
	AL1	US-5,587,363-B1	12-24-1996	Henderson	
	AM1	US-5,589,577-B1	12-31-1996	Peltonen et al.	
	AN1	US-5,658,767-B1	08-19-1997	Kyle	
	AO1	US-5,668,172-B1	09-16-1997	Gallagher et al.	
	AP1	US-5,670,695-B1	09-23-1997	Di Napoli	
	AQ1	US-5,770,209-B1	06-23-1998	Grotendorst et al.	
	AR1	US-5,843,919-B1	12-01-1998	Burger	
	AS1	US-5,891,465-B1	04-06-1999	Keller et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	024047.370B-US02

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-WO 88/07060	09-22-1988			
	BB	GB-UK 2 223 943-A1	04-25-1990			
	BC	EP-EP 0 609 001-A2	08-03-1994			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Ackerman, Lowell, "Dermatologic Uses of Fatty Acids in Dogs and Cats," Veterinary Medicine (December 1995).			
	CB	Ackerman, Lowell, "Reviewing the Biochemical Properties of Fatty Acids," Veterinary Medicine (December 1995).			
	CC	Ahrens, F., Pharmacology, Williams & Wilkins, pp. 174-75 (1996).			
	CD	Amin, A.R. et al., "A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses," Proc. Natl. Acad. Sci. USA 93(24): 14014-9, abstract (Nov. 26, 1996).			
	CE	Anderson, M.A. et al., "Results of a Survey of Small-Animal Practitioners on the Perceived Clinical Efficacy and Safety of an Oral Nutraceutical," Proceedings of AcVS, Orlando, abstract (in press) (Oct. 1997).			
	CF	Arduini, A., "Possible Mechanism of Inhibition of Nitrite-Induced Oxidation of Oxyhemoglobin by Ergothioneine and Uric Acid," Arch. Biochem. Biophys., 294(2): 398-403, abstract (May 1992).			
	CG	Artrodar Diacerein.			
	CH	Aruoma, O.I. et al., "Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite," Biochem. Biophys. Res. Commun. 231(2): 389-91, abstract (Feb. 13, 1997).			
	CI	Asmus, K.D. et al., "One-electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C," Biochem. J. 315(Pt. 2): 625-9, abstract (1996).			
	CJ	Baldessarini, R., "Neuropharmacology of S-Adenosyl Methionine," American Journal Medicine, 83(5A): 95-103 (1987).			
	CK	Barcelo et al., "Effect of S-Adenosylmethionine on Experimental Osteoarthritis in Rabbits," The American Journal of Medicine, 83(5A): 55-59 (Nov. 20, 1987).			
	CL	Barker, J.D. et al., "Chronic Excessive Acetaminophen Use and Liver Damage," Ann. Intern. Med. 87(3): 299-301, abstract (Sept. 1977).			
	CM	Bartolucci, C., "Chondroprotective action of chondroitin sulfate," Int. J. Tiss. Reac., XIII (6) 311-317 (1991).			
	CN	Beccerica, E., "Diacetyl-rhein and rhein: in vivo and in vitro effect on lymphocyte membrane fluidity," Pharmacol. Res., 22 (3): 277-85 (1990) abstract.			
	CO	Beekman, B. et al., "Doxycycline inhibits collagen synthesis by bovine chondrocytes cultured in alginate," Biochem. Biophys. Res. Commun., 237(1): 107-10, abstract, (Aug. 8, 1997).			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	8	Attorney Docket Number	024047.370B-US02

CP	Beren, J. et al., "Therapeutic Effect of Cosamin on Autoimmune Type II Collagen Induced Arthritis in Rats. Proceedings of the North American Veterinary conference (Innovations and New Product Applications in Veterinary Practice), p. 35 abstract (January 1997).
CQ	Berger et al., "A New Medical Approach to the Treatment of Osteoarthritis," The American Journal of Medicine, 5A: 84-88 (Nov. 20, 1987).
CR	Blotman, F. et al., "Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis," Rev. Rheum. Engl. Ed., 64(120): 825-34.
CS	Boothe, D. et al., "Round Table Discussion of Degenerative Joint Disease in Dogs," Canine Practice, 21(1-4): 1-16 (Jan/Feb. - June/July, 1996).
CT	Borrelli, F. et al., "Additional Pharmacological Aspects of Orgotein, A Metalloprotein with Superoxide-Dismutase Activity," Arzneimittelforschung, 29/1: 781-785 (1979).
CU	Boumediene, K. et al., "Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta 1 and beta 2 in cultured articular chondrocytes," Arthritis Rheum., 42(1): 148-56, abstract (Jan. 1999).
CV	Brandt, K.D., "Compensation and decompensation of articular cartilage in osteoarthritis," Agents Actions, 40(3-4): 232-4, abstract (Nov. 1993).
CW	Brandt, K.D., et al., "Effects of diacerhein in an accelerated canine model of osteoarthritis," Osteoarthritis Cartilage, 5(6): 438-49, abstract (Nov. 1997).
CX	Brooks, P.M., "Clinical management of rheumatoid arthritis," The Lancet, 341: 286-290.
CY	Brummel, M.C., "In Search of a Physiological Function for L-ergothioneine," Med. Hypotheses, 18(4): 351-70 abstract (Dec. 1985).
CZ	Brummel, M.C., "In Search of a Physiological Function for L-ergothioneine, -II," Med. Hypotheses, 30(1): 39-48 (Sept. 1989).
CA1	Bucci, L., "Chondroprotective agents: Glucosamine Salts and Chondroitin Sulfates," Townsend Letter for Doctors, pp. 52-54 (Jan. 1994).
CB1	Cargoni, A. et al., "In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart," Biochem. Biophys. Acta., 1270(2-3): 173-8, abstract (April 24, 1995).
CC1	Carney, M., "Neuropharmacology of S-Adenosyl Methionine," Clinical Neuropharmacology, 9(3): 235-243 (1986).
CD1	Champe, P., Biochemistry, 2nd Edition, J.B. Lippincott Co., Philadelphia, 1994, pp. 248, 250 and 265.
CE1	Champe, P. and Harvey, R.A., "Glycosaminoglycans", Lippincott's Illustrated Reviews: Biochemistry (2nd ed.), pp. 148-151 (1994).
CF1	Clark, D.M., DVM, "The Biochemistry of Degenerative Joint Disease and Its Treatment," Continuing Education Article 9 13(2): 275-281.
CG1	Cotran et al., Pathologic Basis of Disease, p. 423 (1994).
CH1	Cotran, R. et al., Pathologic Basis of Disease, 5th ed., Saunders, 1994, pp. 40-41.
CI1	Debord, P. et al., "Influence of renal function on the pharmacokinetics of diacerein after a single oral dose," Eur. J. Drug Metab. Pharmacokinet, 19(1): 13-9, abstract (Jan-Mar. 1994).
CJ1	Degenhardt, M. et al., "Quality control of pentosane polysulfate by capillary zone electrophoresis using indirect detection," J. Chromatogr. A., 817(1-2): 297-306, abstract (Aug. 21, 1998).
CK1	Di Padova, C., "S-Adenosylmethionine in the Treatment of Osteoarthritis," The American Journal of Medicine, 83(5A): 60-65 (Nov. 20, 1987).
CL1	Dougados, Maxime, "The current Classification of Drugs in Osteoarthritis and the Recommendations for the Development," Eular '96 IX Symposium Madrid, 7-10 October 1996.
CM1	Egorov, S. Yu et al., "Quenching of singlet molecular oxygen by conrosine and related antioxidants. Monitoring 1270-nm phosphorescence in aqueous media," Biochem. Mol. Biol. Int. Ap44(4): 687-94, abstract (1997)
CN1	Ettinger, W.H. et al., "Physical Disability form Knee Osteoarthritis: The Role of Exercise as an

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	8	Attorney Docket Number	024047.370B-US02

		Intervention. Medical Science Sports Exercise, abstract (Dec. 1994).	
CO1		"Fatty Acids in Foods and Their Health Implication."	
CP1		Fransen, M. et al., "A Revised Group Exercise Program for Osteoarthritis of the Knee," Physiother. Res. Int. 2(1): 30-41, abstract.	
CQ1		Fry, S.W. and Seef, L.B., "Hepatotoxicity of Anagesics and Anti-Inflammatory Agents," Gastroenterol. Clin. North Am. 24(4): 875-905, abstract (Dec. 1995).	
CR1		Galli, C., "Dietary Omega 3 and Omega 6 Fatty Acids, Biological Effects and Nutritional Essentiality," 297-307, Plenum Press.	
CS1		Ghosh, P. et al., "Second-Line Agents in Osteoarthritis." In: Second-Line Agents in the Treatment of Rheumatic Diseases. Marcel-Dekker, Inc., New York, pp. 353-427 (1992).	
CT1		Girre, C. et al., "Increased Metabolism of Acetaminophen in Chronically Alcoholic patients," Alcohol Clin. Exp. Res. 17(1): 170-3, abstract (Feb. 1993).	
CU1		Goodman, A. and Gillman, L., The Pharmacological Basis of Therapeutics, 7th ed., MacMillan Publishing Co., pp. 692-95 (1985).	
CV1		Han, J.S., "Effects of Various Chemical Compounds on Spontaneous and Hydrogen Peroxide Induced Reversion in Strain TA104 of Salmonella typhimurium," Mutant Res., 266(2): 77-84 (1992) abstract.	
CW1		Hanson, R.R., et al., "The Clinical Profile of a Glucosamine-Chondroitin Sulfate Compound in a Double-Blinded, Placebo-Controlled, Randomized Trial as a Selective Symptom Modifying Nutraceutical for Navicular Syndrome: Current Data and Perspectives," Veterinary Orthopedic Society, 25th Annual Conference, Snowmass, Colorado (Feb. 21-28, 1998).	
CX1		Hanson, R.R. et al., "Evaluation of the Clinical Efficacy of a Nutraceutical in the Treatment of Navicular Syndrome: A Double-Blinded Placebo-Controlled Randomized Clinical Trial," ACVS Veterinary Symposium, ACVS Abstract No. 38, pp. 9-10 (Oct. 16-19, 1997).	
CY1		Hanson, R.R. et al., "Oral Glycosaminoglycans in Treatment of Degenerative Joint Disease in Horses," Equine Practice, 18(10): 18-22 (Nov./Dec. 1996).	
CZ1		Hanson, R.R. et al., "Oral Treatment with a Glucosamine-chondroitin sulfate compound for DJD in Horses: 25 cases," Equine Practice, pp. 16-22 (1997).	
CA2		Hardie, Elizabeth M., DVM, "Slow-Acting Disease-Modifying Osteoarthritis Agents," Veterinary Clinics of North America: Small Animal Practice, 27(4): 950-952.	
CB2		Hardingham, T.E. et al., "Proteoglycans: Many Forms and Many Functions," FASEB J., 6:861-862, abstract (1992).	
CC2		Hartman, P.E. et al., "Direct interception of mutagens and carcinogens by biomolecules," Basic Life Sci., 61: 35-36, abstract (1993).	
CD2		Hartman, Philip E., "Ergothioneine as Antioxidant," Methods in Enzymology, 186: 310-318, Academic Press, Inc. (1990).	
CE2		Hebborn P. et al., "Action of topically applied arachidonic acid on the skin of patients with psoriasis," Arch. Dermatol., 124(3): 387-91, abstract (Mar. 1988).	
CF2		Hellio, M.P. et al., "The Effects of Glucosamine Sulfate on Human Osteoarthritic Chondrocytes in Vitro Investigation," Euler '96 IX Symposium Madrid, 7-10 October 1996.	
CG2		Henrotin, Y.E. et al., "Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes," Clin. Rheumatol. 17(1): 31-9, abstract (1998).	
CH2		Huber, W., Orgotein-(bovine Cu-Zn superoxide dismutase), an anti-inflammatory protein drug: discovery toxicology and pharmacology," Eur. J. Rheumatol. Inflamm. 4(2): 173-82 (1981).	
CI2		Huber, W. et al., "Superoxide Dismutase Pharmacology and Orgotein Efficacy: New Perspectives," In: Biological and Clinical Aspects of Superoxide and Superoxide Dismutase. Developments in Biochemistry (Bannister, W.H., Bannister, J.V., eds., Elsevier, New York-Amsterdam-Oxford IIB: 395-407 (1980).	
CJ2		Hulse, D., "Treatment Methods for Pain in the Osteoarthritic Patients." In ther veterinary clinics of N. America, small animals practice clinical pharmacology and therapeutics, Vol. 28(2): 373.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	5	of	8	Attorney Docket Number	024047.370B-US02

CK2	Hulse, D.S. et al., "The Effect of Cranial Cruciate Deficient and Reconstructed Stifle Joints in Dogs," Proceedings of the Veterinary Orthopedic Society, San Francisco, CA (in press) 1998).	
CL2	Janicak, P.G. et al., S-Adenosylmethionine in Depression, Alabama Journal of Medical Sciences, 25(3): 306-313 (1988).	
CM2	Jepsen, J.V. et al., "Long-term experience with pentosanpolysulfate in interstitial cystitis," Urology, 51(3): 381-7, abstract (Mar. 1998).	
CN2	Jimenez, S.A. and Dodge, G.R., "The Effects of Glucosamine Sulfate on Chondrocyte Gene Expression," Euler '96 IX Symposium, Madrid, 7-10 October 1996.	
CO2	Katori, M. and Majima, M., "[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]," Nippon Yakurigaku Zasshi, 109(6): 247-58, abstract (June 1997).	
CP2	Katzung, M.D., Ph.D. and Bertram, G., "Other Analgesics, Acetaminophin. In Basic and Clinical Pharmacology, Appleton and Lang, pp. 551-2 (1995).	
CQ2	Kent, L. et al., "Differential Response of Articular Chondrocyte Populations to Thromboxane B2 and Analogs of Prostaglandin Cyclic Endoperoxidases," Prostaglandins, 19:391-406 (1980).	
CR2	Khaled, Z. et al., "Effects of Suramin-related and Other Clinically Therapeutic Polyanions on Protein Kinase C Activity," Clin. Cancer Res. (1): 113-122., abstract (Jan. 1995).	
CS2	Kilgore, K., "The Semisynthetic Polysaccharide Pentosan Polysulfate Prevents Complement-Mediated Myocardial Injury in the Rabbit Perfused Heart," J. Pharmacol., Exp. Ther., 285 (3): 987-94 (1998) abstract.	
CT2	Kirkpatrick, C.J., "Effects of Prostanoid Precursors and Indomethacin on Chick Embryonic Cartilage Growth in Organ Culture," Exp. Cell. Biol., 51:1922-200 (1993).	
CU2	Kirkpatrick, C.J. and Gardner, D.L., "Influence of PGA1 on Cartilage Growth," Experientia, 33 (4): 504 (1976).	
CV2	Koopman, W.J., Arthritis and Allied Conditions, A Textbook of Rheumatology, 13(2): 2020-2022.	
CW2	Lamaud, M.E., et al., "Biochemical modifications of connective tissue induced by the non-saponifiables of avocado and soy-bean oils administered percutaneously in the 'hairless' rat," Pathol. Biol., 26(5):269-74, abstract.	
CX2	Lance, R., Ph.D., et al., "Drug Information Handbook," Lexi-Comp. Inc., American Pharmaceutical Associate, 4: 1-3; 12-15 (1997-98).	
CY2	La Villa, G., et al., "Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure," Eur. J. Clin. Pharmacol., 37(1): 1-5, abstract (1989).	
CZ2	Lieber, C.S., "Biochemical Factors in Alcoholic Liver Disease," Seminars in Liver Disease, 13(2): 136-153 (1993).	
CA3	Lindgren, A. et al., "Paracetamol-induced Cholestatic and Granulomatous Liver Injuries," J. Intern. Med. 241(5): 435-9, abstract (May 1997).	
CB3	Lindh, C., et al., "Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc," Scand. J. Rheumatol., 26(6): 468-72.	
CC3	Lippiello, L. et al., "Cartilage Stimulatory and Antiproteolytic Activity is Present in Sera of Dogs Treated with a Chondroprotective Agent," Canine Practice, 24(1) (Jan./Feb. 1999).	
CD3	Lippiello, L. et al., "Modification of Articular Cartilage Chondrocyte Metabolism by In Vitro Enrichment with Fatty Acids," Trans. Orthop. Res. Soc., 12: 162 (1998).	
CE3	Lippiello, L., "Lipid and cell metabolic changes associated with essential fatty acid enrichment of articular chondrocytes," In: Chondrocyte Response to Lipid Loading, Society of Experimental Biology and Medicine (June 1990).	
CF3	Lippiello, Louis, "Prostaglandins and articular cartilage metabolism: Does prostaglandin perturbation perpetuate cartilage destruction?," Osteoarthritis Symposium, University of Nebraska Medical Center, Omaha, Nebraska, pp. 87-88.	
CG3	Maheu, E. et al., "Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	6	of	8	Attorney Docket Number	024047.370B-US02

		of osteoarthritis," Arthritis Rheum. 41(1): 81-91 (Jan. 1998).	
	CH3	Marshall, J.L. et al., "Phase I Trial of Orally Administered Pentosan Polysulfate in Patients with Advanced Cancer," Clin. Cancer Res., 3(12): 2347-2354, abstract (Dec. 1997).	
	CI3	Martel-Pelletier, J. et al., "In vitro effects of diacerhein and rein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes," J. Rheumatol., 25(4): 753-62, abstract (April 1998).	
	CJ3	Mathews, C., Biochemistry, 2nd ed., Benjamin/Cummings publishing co., Menlo Park, CA, p. 551 (1996).	
	CK3	Matthews, C.K. & van Holde, K.E., Biochemistry, 2nd ed., The Benjamin/cummings Pub. Co., 1996, p. 691.	
	CL3	McCord, J.M., "Phagocyte-produced Free Radicals: Roles in Cytotoxicity and Inflammation," Ciba Foundation Symposium 65. Excerpta Medica, Amsterdam-Oxford-New York, pp. 343-360 (1979).	
	CM3	McNamara, P. et al., "Hematologic, Hemostatic, and Biochemical Effects in Dogs Receiving an Oral Chondroprotective Agent for Thirty Days," Am. J. Vet. Res. 57(9): 1390-1394, abstract (1996).	
	CN3	McNamara, P.S. et al., "Effects of an Oral Chondroprotective Agent (Cosequin) on Cartilage Metabolism and Canine Serum," Veterinary Orthopedic Society, 24th Annual Conference, p. 35 (Mar. 1-8, 1997).	
	CO3	McNamara, Paul S., DVM, et al., "Slow-Acting Disease-Modifying Osteoarthritis Agents," Veterinary Clinics of North America: Small Animal Practice, 27(4): 863-867 (Jul. 1997).	
	CP3	Mian, M., "Experimental Studies on Diacerhein: Effects on the Phagocytosis of Neutrophil Cells from Subcutaneous Carregeenan-Induced Exudate," Drugs Exp. Clin. Res., 13(11): 695-8 (1987) abstract.	
	CQ3	Miller et al., "Treatment of Dogs with Hip Arthritis with a Fatty Acid Supplement, Canine Practice, 17(6): 6-8 (Nov./Dec. 1992).	
	CR3	Mimata, H. et al., "Effects of thiols on prostraglandin synthesis in bovine bladder-epithelium," Urol. Int. 50(3): 129-32, abstract (1993).	
	CS3	Mooney, M.A. et al., "Evaluation of the effects of omega-3 fatty acid-containing diets on the inflammatory stage of wound healing in dogs," AM. J. Vet. Res., 59(7):859-63, abstract (July 1998).	
	CT3	Moore, A.R. et al., "Effects on diacerhein on granuloma induced cartilage breakdown in the mouse," Osteoarthritis Cartilage, 6(1):19-23, abstract (Jan. 1998).	
	CU3	Morrison, L.M., MD, et al., "Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans), (1974).	
	CV3	Morykwas, M.J. et al., "Arachidonic acid metabolites: effects on inflammation of fetal rabbit excisional wounds," Inflammation, 16(3): 251-8, abstract (June 1992).	
	CW3	Nakamura, M., "Archindonic Acid Stimulates Corneal Epithelial Migration," J. Ocul. Pharmacol., summer: 10(2): 453-9 abstract.	
	CX3	Newton, G. L. et al., "Low-molecular-weight thiols in streptomycetes and their potential role as antioxidants," J. Bacteriol. 175(9): 2734-42, abstract (May 1993).	
	CY3	Nguyen, M. et al., "Diacerhein in the treatment of osteoarthritis of the hip," Arthritis Rheum., 37(4): 529-36, abstract (Apr. 1994).	
	CZ3	Nicolas, P. et al., "Clinical pharmacokinetics of diacerein," Clin. Pharmacokinet, 35(5): 347-59, abstract (Nov. 1998).	
	CA4	Oyanagui, Y., "Inflammation and Superoxide Production by Macrophages," Trends in Inflammation Research 1, Agents Actions, Suppl., 7: 174-179 (1980).	
	CB4	Paroli, E. et al., "A Pharmacological Approach to Glycosaminoglycans," Drugs under Experimental and Clinical Research 17(1): 9-19 (1991).	
	CC4	Paulikova, H. et al., "The effect of heparin and pentosan polysulfate on the thermal stability of yeast alcohol dehydrogenase," Biochem. Mol. Biol. Int., 46(5): 887-94, abstract (Dec. 1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	7	of	8	Attorney Docket Number	024047.370B-US02

CD4	Phan, S.H. et al., "Regulation of MO-derived FGF Release by Arachadonate Metabolites," J. Leukoc. Biol., 42(2): 106-13, abstract (1987).
CE4	Pietrangelo, A. et al., "Diacerhein blocks iron regulatory protein activation in inflamed human monocytes," Life Sci., 63(14): PL213-9, abstract (1998).
CF4	Piperno, M. et al., "Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro," Osteoarthritis and Cartilage Journal of the OsteoArthritis Research Society International, 8: 207-212 (2000).
CG4	Pipitone, V.R., "Chondroprotection with Chondroitin Sulfate," Drugs under Research, Drugs Exptl. Clin. Res. XVII(1) 3-7, 1991.
CH4	Pomarelli, P. et al., "A nonsteroidal anti-inflammatory drug that stimulates prostaglandin release," Farmaco (Sci) 35(10): 836-42, abstract (Oct. 1980).
CI4	Retzinger, G.S. et al., "Adsorption of fibrinogen to droplets of liquid hydrophobic phases: functionality of the bound protein and biological implications," Arterioscler. Thromb. Vasc. Biol., 18(12): 1948-57, abstract (Dec. 1998).
CJ4	Robertson, J.T., "Prostaglandin production after experimental discectomy," Spine, 21(15): 1731-6, abstract (Aug. 1996).
CK4	Roden, Lennart, "Effect of Hexosamines on the Synthesis of Chondroitin Sulphuric Acid in Vitro," Ark. Kemi., (10): 345-352, abstract (1984).
CL4	Rose, S.R., "Subtleties of Managing Acetaminophen Poisoning," Am. J. Hosp. Pharm. 51(24): 3065-8 (Dec. 15, 1994).
CM4	Rovati, L.C., "The Practical Clinical Development of a Selective Drug for Osteoarthritis: Glucosamine Sulfate," Euler '96 IX Symposium, Madrid, 7-10 October 1996.
CN4	Ryan, M., "Potential of Tetracyclines to Modify Cartilage Breakdown in Osteoarthritis," Curr. Opin. Rheumatol., 8 (3): 238-47 (1996) abstract.
CO4	Scharrer, E. et al., "Stimulation of mucosal uptake of selenium from selenite by some thiols at various sites of rat intestine," Biol. Trace Elem. Res. 33: 109-20, abstract (Apr-Jun. 1992).
CP4	Shires, T.K. et al., "Egothioneine distribution in bovine and porcine ocular tissues," Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol., 117(2): 117-20, abstract (May 1997).
CQ4	Smith, G.N., Jr., et al., "Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage," J. Rheumatol.. 25(3): 532-5, abstract (Mar. 1998).
CR4	Smith, R.C. et al., "Inhibition by thiols of copper(II)-induced oxidation of oxyhemoglobin," Chem. Biol. Interact., 82(2): 209-17, abstract (Apr. 15, 1992).
CS4	Spencer, C., "Diacerein," Drugs, 53(1): 98-106 (1997).
CT4	Srinivasan, B.D., "Corneal reepithelialization and anti-inflammatory agents," Trans. AM Ophthalmol. Soc., 80:758-822, abstract (1982).
CU4	Stramentinoli, G., Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics, Am. J. Med., 83(5A): 35-42 (1987).
CV4	Thiers, M.H., "Unsaponifiable constituents of avocado and soya oils. Treatment of certain forms of arthralgia." J. Med. Lyon 53(222): 195-8 (English summary, p. 198) (Feb. 1972).
CW4	Todhunter, R.J. et al., "Effects of Exercise and Polysulfated Glycosaminoglycan on the Development of Osteoarthritis in Equine Carpal Joints with Osteochondral Defects," Vet. Surgery, 22(5): 330-342, abstract.
CX4	Trentham, D.E. et al., "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis," Science, 261: 1727-30 (September 24, 1993).
CY4	Trentham, David E., "Evidence That Type II Collagen Feeding Can Induce a Durable Therapeutic Response in Some Patients with Rheumatoid Arthritis," Ann. N.Y. of Academy Sciences, pp. 778-306-14 (1996).
CZ4	Trevoux, R., "Unsaponifiable fractions of the avocado and soybean in gynecology," J. Gynecol. Obstet. Biol. Reprod. 6(1): 99-105 (article in French) (English abstract) (Jan. 1977).
CA5	Van der Kraan, P.M. et al., "The Effect of Chronic Paracetamol Administration to Rats on the

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	8	of	8	Attorney Docket Number	024047.370B-US02

		Glycosaminoglycan Content of Patellar Cartilage," Agents Actions, 29(3-4): 218-223, abstract (March 1990).	
	CB5	Vam Der Kraan, P.M. et al., Inhibition of Glycosaminoglycan Synthesis in Anatomically Intact Rat Patellar Cartilage by Paracetamol-induced Serum Sulfate Depletion," Biochem. Pharmacol. 37(19): 3683-3690, abstract.	
	CC5	Villani, P. and Bouvenot, G., "Assessment of the Placebo Effect of symptomatic Slow-Acting Anti-Arthritics," Med. Press, published on PubMed Central-indexed for MEDLINE (Feb. 7, 1998).	
	CD5	Wallace, J.L. et al., "Comparison of the damage-promoting effects of leukotrienes derived from eicosapentaenoic acid and arachidonic acid on the rat stomach," J. Exp. Med., 171(5): 1827-32, abstract (May 1990).	
	CE5	Yu, L.P., Jr., et al., "Effects of oral doxycycline administration on histomorphometry and dynamics of subchondral bone in a canine model of osteoarthritis," J. Rheumatol. 23 (1): 137-42, abstract (Jan. 1996).	
	CF5	Yunmbam, M.K., "Inhibition of breast cancer in nude mouse model by anti-angiogenesis," Oncol. Rep., 5(6): 1431-7, abstract (Nov-Dec. 1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--